Clear Harbor Asset Management LLC Has $1.03 Million Stake in Revolution Medicines, Inc. $RVMD

Clear Harbor Asset Management LLC grew its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 61.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 22,110 shares of the company’s stock after buying an additional 8,394 shares during the period. Clear Harbor Asset Management LLC’s holdings in Revolution Medicines were worth $1,033,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in RVMD. SG Americas Securities LLC grew its position in Revolution Medicines by 150.4% during the third quarter. SG Americas Securities LLC now owns 10,714 shares of the company’s stock worth $500,000 after buying an additional 6,436 shares in the last quarter. Avanza Fonder AB grew its holdings in shares of Revolution Medicines by 17.5% during the 3rd quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock worth $202,000 after purchasing an additional 647 shares in the last quarter. Voya Investment Management LLC increased its position in shares of Revolution Medicines by 2.0% during the third quarter. Voya Investment Management LLC now owns 47,534 shares of the company’s stock valued at $2,220,000 after purchasing an additional 921 shares during the period. GAMMA Investing LLC raised its stake in shares of Revolution Medicines by 45.1% in the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares in the last quarter. Finally, Praxis Investment Management Inc. bought a new position in Revolution Medicines in the third quarter worth $216,000. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Reports that Merck is in talks to acquire Revolution Medicines for roughly $30–32 billion, a direct M&A bid narrative that can justify a sizable takeover premium and is the primary driver of today’s rally. Merck in talks (WSJ)
• Positive Sentiment: Takeover buzz broadened as media reported additional suitors and renewed buyout interest (markets often bid target stocks higher on competing-acquirer speculation). Takeover buzz, another suitor emerges (Barron’s)
• Positive Sentiment: FDA granted Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutant NSCLC — a substantive clinical/regulatory win that strengthens RVMD’s strategic value to acquirers and supports a higher acquisition valuation. Breakthrough Therapy Designation (GlobeNewswire)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates aggressive bullish/speculative positioning by traders ahead of or on takeover rumors, amplifying short-term upside momentum. (market reports)
• Neutral Sentiment: The stock experienced a temporary LULD (limit up/limit down) pause during trading, a procedural volatility-control measure that often accompanies sudden price moves but does not change fundamentals.
• Negative Sentiment: Earlier takeover reports referenced AbbVie interest but AbbVie publicly denied talks, which previously triggered volatility and a pullback — a reminder that rumor-driven moves can reverse if potential bidders decline to engage. AbbVie denies talks (Barron’s)
• Negative Sentiment: Revolution remains a loss-making biotech (recent quarterly EPS missed estimates), so absent a takeover premium the stock’s valuation relies on successful late-stage clinical outcomes and eventual commercialization. (company filings/earnings)

Insiders Place Their Bets

In related news, insider Stephen Michael Kelsey sold 25,000 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $48.54, for a total transaction of $1,213,500.00. Following the transaction, the insider owned 284,047 shares in the company, valued at $13,787,641.38. This represents a 8.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jack Anders sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total transaction of $980,000.00. Following the completion of the sale, the chief financial officer owned 108,065 shares of the company’s stock, valued at $10,590,370. The trade was a 8.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 268,792 shares of company stock valued at $20,971,240. 8.20% of the stock is owned by corporate insiders.

Revolution Medicines Stock Up 10.5%

Shares of RVMD opened at $118.64 on Friday. The company has a market capitalization of $22.94 billion, a P/E ratio of -22.95 and a beta of 0.99. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $121.62. The business’s 50 day simple moving average is $76.36 and its 200-day simple moving average is $53.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the previous year, the company posted ($0.94) earnings per share. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RVMD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a report on Wednesday, October 8th. Needham & Company LLC increased their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Raymond James Financial lifted their price objective on Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a report on Friday, October 17th. HC Wainwright upped their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. raised their target price on Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.